OncoMatch/Clinical Trials/NCT06563596
Epco, Zanu, Ritux for R/R FL or MZL
Is NCT06563596 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Zanubrutinib and Rituximab for follicular lymphoma.
Treatment: Zanubrutinib · Rituximab · Epcoritamab — The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+)
Histologically confirmed diagnosis of CD20+ FL (grade 1-3A) or CD20+ MZL (any subtype)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20 monoclonal antibody
Receipt of at least one prior line of therapy for FL or MZL (with prior treatment including a CD20 monoclonal antibody)
Cannot have received: BTK inhibitor
Prior exposure to a BTK inhibitor
Cannot have received: CAR-T cell therapy
Exception: allowed if >100 days prior to first dose of epcoritamab
Treatment with CAR-T therapy within 100 days prior to first dose of epcoritamab
Cannot have received: investigational drug
Treatment with an investigational drug within 4 weeks prior to the first dose of study treatment
Cannot have received: chemotherapy
Exception: CD20 mAbs allowed
Chemotherapy and other non-investigational anti-neoplastic agents (except CD20 mAbs) within 4 weeks prior to the first dose of study treatment
Cannot have received: CD3xCD20 bispecific antibody
Exception: A limited number of patients with BsAb-refractory disease will be permitted to enroll in each cohort
A limited number of patients with BsAb-refractory disease will be permitted to enroll in each cohort (see section 2.5.3). After this limit is reached, patients with BsAb-refractory disease will be excluded.
Lab requirements
Blood counts
Absolute neutrophil count > 1.0x10^9/L unless due to marrow involvement by lymphoma in which case ANC must be >0.5x10^9/L; Platelets > 75 x10^9/L, unless due to marrow involvement by lymphoma, in which case platelets must be >50 x10^9/L
Kidney function
Estimated CrCl (based on Cockcroft Gault or MDRD) ≥ 45ml/min or ≥ 45ml/min/1.73m2
Liver function
Total bilirubin < 1.5 X ULN, unless Gilbert syndrome, in which case direct bilirubin must be < 1.5 x ULN; AST/ALT < 2.5 X ULN, unless documented liver involvement by lymphoma, in which case AST/ALT must be <5 x ULN
Adequate hematologic and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- The Ohio State University Wexner Medical Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify